Pharmaceuticals, Biotechnology and Life Sciences
Deciphera Pharmaceuticals has ended the first quarter 2020 with cash, cash equivalents and marketable securities of $691.5 Million, with cash runway expected into the second half of 2022, and posts net loss of $72.8 million.
WALTHAM, Mass.–(BUSINESS WIRE)–Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today…
– Enrollment Completed in INVICTUS Pivotal Phase 3 Clinical Study in
Fourth-line and Fourth-line Plus GIST; Top-line Data Expected in
Mid-2019 –
– INTRIGUE Pivotal Phase 3 Clinical Study Initiated in Second-line
…